|
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Clinical research trials and Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer. Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer  Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
For Condition: Bladder Cancer,Urethral Cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effects of combination chemotherapy with cisplatin, ifosfamide, and paclitaxel in treating patients with metastatic urinary tract cancer that cannot be treated with surgery.
Details: OBJECTIVES: - Determine the efficacy of cisplatin, ifosfamide, and paclitaxel in patients with unresectable or metastatic urothelial cancer (nontransitional cell histologies). OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-3. Filgrastim (G-CSF) is administered subcutaneously daily beginning on day 6 and continuing through day 17 or until blood counts recover. Treatment continues every 3 weeks for a maximum of 6 courses in the absence of stable or progressive disease after completion of course 2 or complete response after completion of course 4. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven unresectable or metastatic urothelial cancer - No transitional cell histologies - Bidimensionally measurable disease PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Hematopoietic: - WBC at least 3,500/mm^3 - Platelet count greater than 150,000/mm^3 Hepatic: - Bilirubin less than 2.0 mg/dL Renal: - Creatinine less than 1.5 mg/dL OR - Creatinine clearance greater than 55 mL/min Cardiovascular: - No New York Heart Association class III or IV heart disease Other: - No other concurrent malignancy except basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior systemic chemotherapy Endocrine therapy - Not specified Radiotherapy - At least 3 weeks since prior radiotherapy Surgery - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DeanBajorin, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Dean Bajorin 646-422-4333
Additional Information:
Study ID Numbers: CDR0000064373; MSKCC-95031,NCI-V95-0743
Study Start Date:
Record last reviewed: March 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002684
Other Bladder Cancer Studies:
1. Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
2. Bortezomib in Treating Patients With Advanced Transitional Cell Carcinoma of the Urothelium
3. BMS-247550 in Treating Patients With Advanced Urinary Tract Cancer
4. Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
5. LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Related Studies:
Other Bladder Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
|
|
|
|
|
|
|
|
